J&J meets Q4 expectations with $21.4B in sales as it stares down patent cliff

John­son & John­son met its fore­casts for the fourth quar­ter of 2023, re­port­ing a 7.3% sales growth to $21.4 bil­lion and full-year re­port­ed sales in­crease of 6.5% to $85.2 bil­lion for the year.

J&J al­so re­con­firmed its 2024 op­er­a­tional sales growth pre­dic­tion of 5% to 6% and said it ex­pects sales to be high­er in the first half of the year com­pared to the sec­ond.

In Q4 of 2023, US sales brought in around $12 bil­lion (a jump from $10 bil­lion in 2022) and $9.3 bil­lion in­ter­na­tion­al­ly for a to­tal of $21.3 bil­lion. Its in­no­v­a­tive med­i­cine port­fo­lio in­creased by 7.2% world­wide, led by on­col­o­gy prod­ucts, in­clud­ing Er­lea­da and Carvyk­ti, as well as Ste­lara in im­munol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.